A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly (CHOLINE)
A Multicentre, Randomised, Double-blind, Placebo-controlled Study of the Efficacy of Supplementary Treatment With Cholecalciferol (Vitamin D3) in Patients With Relapsing- Multiple Sclerosis (RMS) Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly
Sponsor: Merck KGaA, Darmstadt, Germany
A PHASE2 clinical study on Multiple Sclerosis, this trial is completed. The trial is conducted by Merck KGaA, Darmstadt, Germany and has accumulated 7 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2019 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Dec 2017 [monthly]
Completed PHASE2
First recorded
Nov 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck KGaA, Darmstadt, Germany
- Merck Serono S.A.S, France
For direct contact, visit the study record on ClinicalTrials.gov .